Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Company Overview

Oncotelic Therapeutics, trading on the OTCMKTS under the symbol OTLC, is a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies. The company leverages proprietary platforms in oncolytic virotherapy and targeted gene modulation to design treatments that selectively destroy tumor cells while sparing healthy tissue. By harnessing the immune system’s natural defenses, Oncotelic aims to address high unmet needs in solid tumors and rare malignancies.

The company’s lead candidate is an engineered oncolytic virus designed to replicate preferentially within cancer cells, triggering immunogenic cell death and promoting systemic anti-tumor immunity. In parallel, Oncotelic is advancing a portfolio of small-molecule inhibitors that target key oncogenic pathways implicated in tumor growth and resistance. Research collaborations with academic institutions and contract development partners support preclinical validation and manufacturing scale-up, positioning the pipeline for upcoming clinical trials in multiple oncological indications.

Founded in the early 2010s and headquartered in Massachusetts, Oncotelic Therapeutics has established R&D operations in both North America and Europe, facilitating global regulatory interactions and patient access strategies. The management team combines decades of experience in oncology drug development, clinical operations and regulatory affairs. Under the leadership of CEO Dr. Laura Jensen and Chief Scientific Officer Dr. Michael Patel, the company continues to pursue strategic partnerships and licensing opportunities to accelerate its programs toward commercialization.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.04 to $0.07
• 52-Week Range: $0.02 to $0.07
• Volume: 63,727 shs
• Average Volume: 121,504 shs
• Market Capitalization: $20.70 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oncotelic Therapeutics Stock Analysis - MarketRank™

Oncotelic Therapeutics scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oncotelic Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncotelic Therapeutics is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncotelic Therapeutics is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oncotelic Therapeutics has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Oncotelic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncotelic Therapeutics has recently decreased by 35.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncotelic Therapeutics does not currently pay a dividend.

Dividend Growth

Oncotelic Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Oncotelic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncotelic Therapeutics has recently decreased by 35.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Oncotelic Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

OTLC Stock Analysis - Frequently Asked Questions

How have OTLC shares performed this year?

Oncotelic Therapeutics' stock was trading at $0.0350 at the beginning of the year. Since then, OTLC stock has increased by 44.9% and is now trading at $0.0507.

How were Oncotelic Therapeutics' earnings last quarter?

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) issued its quarterly earnings results on Thursday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02.

How do I buy shares of Oncotelic Therapeutics?

Shares of OTLC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oncotelic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncotelic Therapeutics investors own include MariMed (MRMD), First Wave BioPharma (FWBI), DSS (DSS), Cemex (CX), CohBar (CWBR), ContraFect (CFRX) and Avid Bioservices (CDMO).

Company Calendar

• Last Earnings: 8/19/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:OTLC
• CIK: 908259
• Web: www.mateon.com
• Phone: (650) 635-7000
• Fax: 650-635-7001
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.52 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -14.16%
• Return on Assets: -4.41%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.01
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 295.72
• Cash Flow: $0.01 per share
• Price / Cash Flow: 9.95
• Book Value: $0.02 per share
• Price / Book: 2.54

Miscellaneous

• Outstanding Shares: 408,290,000
• Free Float: 248,160,000
• Market Cap: $20.70 million
• Optionable: Not Optionable
• Beta: -0.75